Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Medifast Inc    MED

MEDIFAST INC

(MED)
  Report  
Delayed Quote. Delayed Nyse - 09/13 06:30:00 pm
106.05 USD   +0.98%
09/12MEDIFAST, INC. : Announces Quarterly Dividend
PR
09/03MEDIFAST INC : Underpinned by a support level
08/01MEDIFAST : 2Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Medifast Inc : Underpinned by a support level

share with twitter share with LinkedIn share with facebook
share via e-mail
09/03/2019 | 09:39am EDT
long trade
Live
Entry price : 99.23$ | Target : 114.9$ | Stop-loss : 93.45$ | Potential : 15.79%
Medifast Inc shares are closing back in on major support levels around 100 USD based on daily price data, which could offer attractive entry points.
Investors have an opportunity to buy the stock and target the $ 114.9.
Chart MEDIFAST INC
Duration : Period :
Medifast Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 88.76, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • The underlying tendency is negative on the weekly chart below the resistance at 155.1 USD
Ratings chart
Subsector Special Foods & Welbeing Products
1st jan.Capitalisation (M$)Investor Rating
MEDIFAST INC-16.00%1 255
BY-HEALTH CO LTD--.--%4 405
BALCHEM CORPORATION33.36%3 408
SIMPLY GOOD FOODS CO59.37%2 462
-
BLACKMORES LIMITED-36.97%920
GRAPE KING BIO LTD--.--%828
BIOGAIA AB33.23%776
JAMIESON WELLNESS INC12.14%684
KOLMARBNH CO LTD--.--%678
MIDSONA AB-11.53%260
CLOVER CORPORATION LIMITED54.01%239
Autres valeurs du secteur

Patrick Rejaunier
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2019 750 M
EBIT 2019 105 M
Net income 2019 83,4 M
Finance 2019 114 M
Yield 2019 -
P/E ratio 2019 15,5x
P/E ratio 2020 12,5x
EV / Sales2019 1,52x
EV / Sales2020 1,18x
Capitalization 1 255 M
Upcoming event on MEDIFAST INC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 195,00  $
Last Close Price 106,05  $
Spread / Highest target 136%
Spread / Average Target 83,9%
Spread / Lowest Target 24,5%
EPS Revisions
Managers
NameTitle
Daniel R. Chard Chief Executive Officer & Director
Michael C. MacDonald Non-Executive Chairman
Timothy G. Robinson CFO & Principal Accounting Officer
Bill Baker Executive Vice President-Information Technology
Kevin G. Byrnes Independent Director